Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice
Journal of Controlled Release · 2023-09 · 361 · 592-603
DOI: 10.1016/j.jconrel.2023.08.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-09. Verfasst von Mahmoud A Younis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Department of Industrial Pharmacy, Facul…. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Nanoparticles. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Hokkaido University, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
We report on a novel strategy for treating liver fibrosis through reprogramming activated Hepatic Stellate Cells (aHSCs) into quiescent Hepatic Stellate Cells (qHSCs) using siRNA-loaded lipid nanoparticles (LNPs). The in vivo screening of an array of molecularly-diverse ionizable lipids identified two candidates, CL15A6 and CL15H6, with a high siRNA delivery efficiency to aHSCs. Optimization of the composition and physico-chemical properties of the LNPs enabled the ligand-free, selective, and potent siRNA delivery to aHSCs post intravenous administration, with a median effective siRNA dose (ED50) as low as 0.08 mg/Kg. The biosafety of the LNPs was confirmed by escalating the dose to 50-fold higher than the ED50 or by chronic administration. The recruitment of the novel LNPs for the simultaneous knockdown of Hedgehog (Hh) and Transforming Growth Factor Beta 1 (TGFβ1) signaling pathways using an siRNA cocktail enabled the reversal of liver fibrosis and the restoration of the normal liver function in mice. Analysis of the key transcription factors in aHSCs suggested that the reprogramming of aHSCs into qHSCs mediated the therapeutic outcomes. The scalable ligand-free platform developed in this study as well as the novel therapeutic strategy reported herein are promising for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. Electronic add…
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
- Department of Histology and Cytology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt; Graduate School of Veterinary Medicine, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo 060-0818, J…
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan. Electronic address: harasima@pharm.hokudai.ac.jp.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Hokkaido University
- Japan Society for the Promotion of Science
Zitieren
APA
Younis, M. A., Sato, Y., Elewa, Y. H. A., & Harashima, H. (2023). Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice. Journal of Controlled Release, 361, 592-603. https://doi.org/10.1016/j.jconrel.2023.08.021
Vancouver
Younis MA, Sato Y, Elewa YHA, Harashima H. Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice. Journal of Controlled Release. 2023;361:592-603. doi:10.1016/j.jconrel.2023.08.021
BibTeX
@article{Younis2023,
author = {Younis, Mahmoud A and Sato, Yusuke and Elewa, Yaser H A and Harashima, Hideyoshi},
title = {Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice},
journal = {Journal of Controlled Release},
year = {2023},
volume = {361},
pages = {592--603},
doi = {10.1016/j.jconrel.2023.08.021}
}
EUVIMED